Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 18;28(1):48-58.
doi: 10.1093/oncolo/oyac209.

Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs

Zhonglin Hao  1 , Saurabh Parasramka  1 , Quan Chen  2 , Aasems Jacob  1 , Bin Huang  2   3 , Timothy Mullett  4 , Al B Benson  5
Affiliations

Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs

Zhonglin Hao et al. Oncologist. .

Abstract

Background: Overall survival advantage of chemotherapy before versus after metastasectomy of liver or lung lesion is not clear for colon cancer with synchronous liver or lung metastasis.

Materials and methods: Adults 20 years or older with primary colon cancer and single organ metastatic disease either in the liver or lung at diagnosis were identified between 2010 and 2015 through the National Cancer Database (NCDB). Patients were categorized into 2 cohorts: pre-operative/peri-operative chemotherapy (neoadjuvant -[NAC]) or post-operative chemotherapy (adjuvant [AC]). Survivals and factors associated with were compared between the 2 groups.

Results: A total of 3038 patients with colon cancer with liver or lung metastases were identified. The percentage of patients receiving NAC had steadily increased from 12.29% to 28.31%, mostly in academic programs. On multivariate analysis, patients who received NAC had an overall survival advantage in the non-academic setting whereas no advantage is seen in the patients treated in the academic settings. The median overall survival for patients receiving NAC and AC was 47.24 months and 38.08 months, respectively. Factors associated with overall survival advantage in NAC patients treated in non-academic programs included age 20-49 years, CEA value of >30, right-sided colon primary, liver metastasis, and clear resection margins.

Conclusions: Metastatic colon cancer with single organ liver or lung lesions benefits from neoadjuvant chemotherapy, especially in -non-academic settings. The overall survival advantage in this setting has not been shown before.

Keywords: adjuvant chemotherapy; colon cancer; liver/lung metastasis; neoadjuvant chemotherapy; surgery; survival.

PubMed Disclaimer

Conflict of interest statement

Zhonglin Hao: Bayer Inc (RF), Pfizer (C/A), BeiGene (C/A). Al. B. Benson: Merck Sharpe and Dohme, Taiho, Signatera (Natera), Mirati,Boston Scientific, HalioDx, Xencor, Apexigen,Grail, Bioascend,Pfizer, Tukyska, Hutchmed (C/A), Astellas, Tyme, Novartis, BMS, Amgen (Data Monitoring Committee). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.

Figures

Figure 1.
Figure 1.
CONSORT diagram.
Figure 2.
Figure 2.
ABC. Neoadjuvant and adjuvant chemo in academic vs non-academic programs (trend).
Figure 3.
Figure 3.
ABC. Survival curve of patients with different sequence of treatment (NAC vs AC).
Figure 4.
Figure 4.
Mortality hazard ratios according to baseline co-variants in non-academic programs.
See this image and copyright information in PMC

Comment in

References

    1. Van Cutsem E, Nordlinger B, Adam R, et al. . Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212-2221. 10.1016/j.ejca.2006.04.012. - DOI - PubMed
    1. Alberts SR, Horvath WL, Sternfeld WC, et al. . Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243-9249. 10.1200/JCO.2005.07.740. - DOI - PubMed
    1. Lee WS, Yun SH, Chun HK, et al. . Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007;22(6):699-704. 10.1007/s00384-006-0218-2. - DOI - PubMed
    1. Kanas GP, Taylor A, Primrose JN, et al. . Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012;4(1):283-301. 10.2147/CLEP.S34285. - DOI - PMC - PubMed
    1. Abdalla EK, Adam R, Bilchik AJ, et al. . Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271-1280. 10.1245/s10434-006-9045-5. - DOI - PubMed

Publication types